RxDoctor Payments Data

Jennifer White Slough, APRN

Nurse Practitioner · Wamego, KSNPI 1750646238

Payments from drug & device makers

$1,225in general payments, 2019–2025

Across 44 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$637
  • Novo Nordisk$186
  • AbbVie$105
  • Lilly USA, LLC$91
  • Amgen$43
  • Acadia Pharmaceuticals Inc$32
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$1,225100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,225 in reported general payments places this provider in the 75th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$12,435
Medicare patients
59
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide15$16,328
MounjaroTirzepatide17$15,171
FarxigaDapagliflozin Propanediol23$13,492
EliquisApixaban14$12,757
OzempicSemaglutide12$11,435
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,197
Pregabalin22$1,006
Estradiol (Twice Weekly)Estradiol12$597
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$529
Atorvastatin Calcium57$512
Albuterol Sulfate HfaAlbuterol Sulfate11$441
Losartan Potassium38$396
Levothyroxine Sodium36$385
Potassium Chloride14$319
Fluoxetine Hcl14$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$186$27,76327 claims
AstraZenecaFarxiga, Breztri Aerosphere$637$19,68934 claims
Lilly USA, LLCMounjaro$91$15,17117 claims
PfizerEliquis$26$12,75714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Wamego

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →